Health
BioNTech Starts Malaria Trial in New Test for mRNA Vaccines
- Study will test three different doses on 60 patients
- Biotech company seeks to follow Covid vaccine with new drugs
This article is for subscribers only.
BioNTech SE has begun human trials on a vaccine for malaria, a fresh test for the messenger RNA technology that powered the most successful immunizations against Covid-19.
The first patient was dosed on Dec. 21, Chief Executive Officer Ugur Sahin said in an interview. The Phase 1 study will enroll 60 patients and use three different doses for a single vaccine candidate, the BioNTech CEO said. The Mainz, Germany-based company plans to evaluate different versions of the shot to see which one works best.